---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-009109"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:44:26.787801+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck reports Q4 GAAP loss of $0.48/share; plans $4B restructuring; FY2024 EPS guidance $8.44-8.59

## Summary
- Q4 2023 GAAP net loss $1.2B ($0.48 loss per share); non-GAAP EPS $0.03, includes $1.69/share Daiichi Sankyo charge.
- Full-year 2023 sales $60.1B (+1% YoY); KEYTRUDA $25B (+19%), GARDASIL $8.9B (+29%), LAGEVRIO down 75% to $1.4B.
- FY 2024 outlook: sales $62.7-64.2B; non-GAAP EPS $8.44-8.59.
- Approved 2024 Restructuring Program with cumulative pretax costs ~$4B; ~60% non-cash; substantially complete by end of 2031.

## SEC filing metadata
- accession: 0001104659-24-009109
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/0001104659-24-009109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/tm244517d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-009109
- JSON: https://secwatch.observer/filing/0001104659-24-009109.json
- Plain text: https://secwatch.observer/filing/0001104659-24-009109.txt

## Key facts
- Earnings Releases
  Merck & Co., Inc. reported fourth quarter and full year of 2023 results: revenue $14.6 billion.
  - Period: fourth quarter and full year of 2023
  - Revenue: $14.6 billion
  - Result: reported results
  source text: Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results - Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines - Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/0001104659-24-009109-index.htm
- Restructurings & Charges
  Merck & Co., Inc. announced a restructuring with charges of approximately $4.0 billion affecting the Company's Human Health global manufacturing network … and also optimize the Animal Health global manufacturing network.
  - Type: restructuring
  - Charge: approximately $4.0 billion
  - Affected area: the Company's Human Health global manufacturing network … and also optimize the Animal Health global manufacturing network
  source text: expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the $4.0 billion will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested; the remainder of the costs
  evidence_url: https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/0001104659-24-009109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.